Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 90
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Ageing ; 19(3): 495-507, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34566550

RESUMEN

Diagnosing dementia can be challenging for clinicians, given the array of factors that contribute to changes in cognitive function. The Addenbrooke's Cognitive Examination III (ACE-III) is commonly used in dementia assessments, covering the domains of attention, memory, fluency, visuospatial and language. This study aims to (1) assess the reliability of ACE-III to differentiate between dementia, mild cognitive impairment (MCI) and controls and (2) establish whether the ACE-III is useful for diagnosing dementia subtypes. Client records from the Northern Health and Social Care Trust (NHSCT) Memory Service (n = 2,331, 2013-2019) were used in the analysis including people diagnosed with Alzheimer's disease (n = 637), vascular dementia (n = 252), mixed dementia (n = 490), MCI (n = 920) and controls (n = 32). There were significant differences in total ACE-III and subdomain scores between people with dementia, MCI and controls (p < 0.05 for all), with little overlap between distribution of total ACE-III scores (< 39%) between groups. The distribution of total ACE-III and subdomain scores across all dementias were similar. There were significant differences in scores for attention, memory and fluency between Alzheimer's disease and mixed dementia, and for visuospatial and language between Alzheimer's disease-vascular dementia (p < 0.05 for all). However, despite the significant differences across these subdomains, there was a high degree of overlap between these scores (> 73%) and thus the differences are not clinically relevant. The results suggest that ACE-III is a useful tool for discriminating between dementia, MCI and controls, but it is not reliable for discriminating between dementia subtypes. Nonetheless, the ACE-III is still a reliable tool for clinicians that can assist in making a dementia diagnosis in combination with other factors at assessment.

2.
Acta Psychiatr Scand ; 141(2): 131-141, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31667829

RESUMEN

OBJECTIVE: Promptly establishing maintenance therapy could reduce morbidity and mortality in patients with bipolar disorder. Using a machine learning approach, we sought to evaluate whether lithium responsiveness (LR) is predictable using clinical markers. METHOD: Our data are the largest existing sample of direct interview-based clinical data from lithium-treated patients (n = 1266, 34.7% responders), collected across seven sites, internationally. We trained a random forest model to classify LR-as defined by the previously validated Alda scale-against 180 clinical predictors. RESULTS: Under appropriate cross-validation procedures, LR was predictable in the pooled sample with an area under the receiver operating characteristic curve of 0.80 (95% CI 0.78-0.82) and a Cohen kappa of 0.46 (0.4-0.51). The model demonstrated a particularly low false-positive rate (specificity 0.91 [0.88-0.92]). Features related to clinical course and the absence of rapid cycling appeared consistently informative. CONCLUSION: Clinical data can inform out-of-sample LR prediction to a potentially clinically relevant degree. Despite the relevance of clinical course and the absence of rapid cycling, there was substantial between-site heterogeneity with respect to feature importance. Future work must focus on improving classification of true positives, better characterizing between- and within-site heterogeneity, and further testing such models on new external datasets.


Asunto(s)
Antimaníacos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Reglas de Decisión Clínica , Compuestos de Litio/uso terapéutico , Aprendizaje Automático , Adulto , Edad de Inicio , Área Bajo la Curva , Trastorno Bipolar/epidemiología , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Curva ROC , Factores de Riesgo , Trastornos del Inicio y del Mantenimiento del Sueño/epidemiología , Resultado del Tratamiento
4.
Mol Psychiatry ; 6(5): 570-8, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11526471

RESUMEN

Genetic mapping studies in bipolar disorder (BD) have been hampered by the unclear boundaries of the phenotypic spectrum, and possibly, by the complexity of the underlying genetic mechanisms, and heterogeneity. Among the suggested approaches to circumvent these problems, a pharmacogenetic strategy has been increasingly proposed. Several studies have indicated that patients with BD who respond well to lithium prophylaxis constitute a biologically distinct subgroup. In this study we have conducted a complete genome scan using 378 markers spaced at an average distance of 10 cM in 31 families ascertained through excellent lithium responders. Response to lithium was evaluated prospectively with an average follow-up of 12 years. Evidence for linkage was found with a locus on chromosome 15q14 (ACTC, lod score = 3.46, locus-specific P-value = 0.000014) and suggestive results were observed for another marker on chromosome 7q11.2 (D7S1816, lod score = 2.68, locus-specific P-value = 0.00011). Other interesting findings were obtained with markers on chromosomes 6 and 22, namely D6S1050 (lod score = 2.0, locus-specific P-value = 0.00004) and D22S420 (lod score = 1.91). Nonparametric linkage analysis provided additional support for the role of these loci. Further analyses of these results suggested that the locus on chromosome 15q14 may be implicated in the etiology of BD, whereas the 7q11.2 locus may be relevant for lithium response. In conclusion, our results provide original evidence suggesting that loci on 15q14 and 7q11.2 may be implicated in the pathogenesis of BD responsive to lithium.


Asunto(s)
Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/genética , Mapeo Cromosómico , Cromosomas Humanos Par 15 , Cromosomas Humanos Par 7 , Predisposición Genética a la Enfermedad , Litio/uso terapéutico , Adulto , Edad de Inicio , Antimaníacos/uso terapéutico , Femenino , Estudios de Seguimiento , Genes Dominantes , Genes Recesivos , Ligamiento Genético , Marcadores Genéticos , Genoma Humano , Humanos , Masculino , Persona de Mediana Edad , Modelos Genéticos , Modelos Estadísticos , Programas Informáticos , Factores de Tiempo
5.
Physiol Res ; 50(1): 43-50, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11300226

RESUMEN

We investigated the association between metamphetamine dependence and TaqI A polymorphism of the dopamine receptor D2 gene (DRD2), I/D polymorphism in angiotensin-converting enzyme (ACE) and M235T polymorphism of the angiotensinogen gene (AGT) in 93 unrelated metamphetamine-dependent subjects and 131 controls. Our results did not prove any association of TaqI A polymorphism of the DRD2 gene, I/D polymorphism of ACE gene, and M235T polymorphism of AGT gene with the metamphetamine dependence in Caucasians of Czech origin. However, a significant difference in allele I frequency between male and female control groups for the I/D ACE polymorphism (p<0.03) was found.


Asunto(s)
Angiotensinógeno/genética , Metanfetamina , Peptidil-Dipeptidasa A/genética , Polimorfismo de Longitud del Fragmento de Restricción , Receptores de Dopamina D2/genética , Trastornos Relacionados con Sustancias/genética , Adulto , Alelos , Desoxirribonucleasas de Localización Especificada Tipo II/metabolismo , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Reacción en Cadena de la Polimerasa , Caracteres Sexuales
6.
Am J Med Genet ; 96(6): 804-7, 2000 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-11121186

RESUMEN

Anticipation has been suggested among the genetic mechanisms of bipolar disorder (BD), prompting the search for unstable DNA sequences. Past studies of anticipation in BD have generally relied on observed shift in the age at onset between parental and offspring generations. Such a shift, however, may be caused by a number of other factors difficult to correct for. We investigated age at onset distributions in a sample of 161 related subjects and in a sample of "pseudofamilies" consisting of 320 unrelated subjects selected from a large epidemiological cohort using Monte-Carlo simulation to mimic the family sample. Comparison of age at onset distributions in both samples shows a difference between the generations, but of a similar magnitude in each sample. This suggests that age at onset alone may not be a sufficient criterion of anticipation. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:804-807, 2000.


Asunto(s)
Anticipación Genética , Trastorno Bipolar/genética , Adulto , Edad de Inicio , Estudios de Cohortes , Salud de la Familia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadística como Asunto
7.
J Psychiatry Neurosci ; 25(4): 353-8, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11022400

RESUMEN

OBJECTIVE: To test for genetic linkage and association with GABAergic candidate genes in lithium-responsive bipolar disorder. DESIGN: Polymorphisms located in genes that code for GABRA3, GABRA5 and GABRB3 subunits of the GABAA receptor were investigated using association and linkage strategies. PARTICIPANTS: A total of 138 patients with bipolar 1 disorder with a clear response to lithium prophylaxis, selected from specialized lithium clinics in Canada and Europe that are part of the International Group for the Study of Lithium-Treated Patients, and 108 psychiatrically healthy controls. Families of 24 probands were suitable for linkage analysis. OUTCOME MEASURES: The association between the candidate genes and patients with bipolar disorder versus that of controls and genetic linkage within families. RESULTS: There was no significant association or linkage found between lithium-responsive bipolar disorder and the GABAergic candidate genes investigated. CONCLUSIONS: This study does not support a major role for the GABAergic candidate genes tested in lithium-responsive bipolar disorder.


Asunto(s)
Antimaníacos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Expresión Génica/genética , Litio/uso terapéutico , Receptores de GABA/genética , Transmisión Sináptica/genética , Alelos , Trastorno Bipolar/genética , Femenino , Ligamiento Genético , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo Genético/genética
8.
Am J Med Genet ; 96(2): 178-81, 2000 Apr 03.
Artículo en Inglés | MEDLINE | ID: mdl-10893493

RESUMEN

Corticotropin-releasing hormone (CRH) and proenkephalin (PENK) are hypothalamic peptides involved in the stress response and hypothalamic-pituitary axis regulation. Previous research has implicated these peptides in the pathogenesis of affective disorders. In this study we investigated two polymorphisms located in the genes that code for CRH and PENK by means of association and linkage analyses. A total of 138 bipolar patients and 108 controls were included in the association study. In addition, 24 families were available for linkage analysis, including six families of probands with documented periodic positivity of dexamethasone suppression tests (DST) during remission. We found no association of bipolar disorder with either gene. Similarly, we did not find any evidence of linkage (P = 0.56 for CRH and 0.52 for PENK) in the entire sample or in the subsample of families of DST positive probands. In conclusion, our study does not support the hypothesis that genes coding for CRH or PENK contribute to the genetic susceptibility to bipolar disorder. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:178-181, 2000.


Asunto(s)
Trastorno Bipolar/genética , Hormona Liberadora de Corticotropina/genética , Encefalinas/genética , Ligamiento Genético/genética , Precursores de Proteínas/genética , Adulto , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/etiología , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Desequilibrio de Ligamiento/genética , Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Fenotipo
9.
J Affect Disord ; 58(1): 63-8, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10760559

RESUMEN

BACKGROUND: Several studies have suggested that expanded trinucleotide repeats, particularly CAG, may have a role in the etiology of BD. Results obtained with the repeat expansion detection technique (RED) have indicated that bipolar patients have an excess of expanded CAG repeats. However, it is not clear which loci account for this difference. METHODS: Using lithium-responsive bipolar patients in order to reduce heterogeneity, we investigated five loci that are expressed in the brain and contain translated CAG repeats. A sample of 138 cases and 108 controls was studied. Genotypes were coded quantitatively or qualitatively and repeat distributions were compared. RESULTS: No difference was found in allele distribution between cases and controls for any of the loci studied. In one locus - L10378 - patients had a tendency to present shorter alleles (28.1 versus 27.9 repeats; t=2.55, df=205, P=0.011), however, this difference disappeared after correction for multiple testing. LIMITATIONS: The study has limitations common to most candidate gene association studies, that is, limited number of loci investigated and limited power to detect loci that account for a small proportion of the total genetic variability. CONCLUSIONS: Our results suggest that the loci investigated have no major role in the genetic predisposition to bipolar disorder.


Asunto(s)
Trastorno Bipolar/genética , Mapeo Cromosómico , Péptidos/genética , Adulto , Anciano , Alelos , Antimaníacos/uso terapéutico , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/tratamiento farmacológico , Femenino , Pruebas Genéticas , Humanos , Carbonato de Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Repeticiones de Trinucleótidos/genética
11.
Psychiatr Genet ; 9(1): 13-6, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10335547

RESUMEN

A number of association studies have investigated the role of the monoamine oxidase A (MAOA) gene in the susceptibility to bipolar disorder. Although some studies have reported positive findings, there remains some controversy, because results from different studies have not been consistent. A common explanation for inconsistencies between studies is genetic heterogeneity. We have focused on lithium responsive bipolar disorder as a way to reduce heterogeneity. In this study, we investigated the role of MAOA in lithium responsive bipolar patients using association and linkage study designs. The investigation used 138 patients and 108 normal controls. In addition, 25 families were also studied. Our results were not supportive of a major role of MAOA in the predisposition to bipolar disorder.


Asunto(s)
Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/genética , Ligamiento Genético/genética , Litio/uso terapéutico , Monoaminooxidasa/genética , Alelos , Femenino , Humanos , Masculino
12.
Mol Psychiatry ; 3(6): 534-8, 1998 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9857980

RESUMEN

Several studies have indicated that patients with bipolar disorder (BD) who respond well to lithium prophylaxis constitute a biologically distinct subgroup. Lithium is thought to stabilize mood by acting at the phosphoinositide cycle. We have investigated a polymorphism located in the gene (PLCG1) that codes for a gamma-1 isozyme of phospholipase (PLC), an enzyme that plays an important role in the phosphoinositide second messenger system. A population-based association study and a family-based linkage study were carried out on patients who were considered excellent responders to lithium prophylaxis. Response to lithium was evaluated prospectively with an average follow-up of 14.4 +/- 6.8 years. The PLCG1 polymorphism was investigated in 136 excellent lithium responders and 163 controls. In addition, the segregation of this marker was studied in 32 families ascertained through lithium-responsive bipolar probands. The allele distributions between lithium-responsive bipolar patients and controls were different, with a higher frequency of one of the PLCG1 polymorphisms in patients (chi2 = 8.09; empirical P = 0.033). This polymorphism, however, confers only a small risk (OR = 1.88, CI 1.19-3.00). Linkage studies with the same marker yielded modest support for the involvement of this gene in the pathogenesis of BD when unilineal families were considered (Max LOD = 1.45; empirical P = 0.004), but not in the whole sample. Our results provide preliminary evidence that a PLC isozyme may confer susceptibility to bipolar disorder, probably accounting for a fraction of the total genetic variance. Whether this polymorphism is implicated in the pathogenesis of BD or in the mechanism of lithium response remains to be determined.


Asunto(s)
Trastorno Bipolar/enzimología , Trastorno Bipolar/genética , Isoenzimas/genética , Isoenzimas/metabolismo , Polimorfismo Genético , Fosfolipasas de Tipo C/genética , Fosfolipasas de Tipo C/metabolismo , Adulto , Edad de Inicio , Trastorno Bipolar/tratamiento farmacológico , Femenino , Frecuencia de los Genes , Genes Dominantes , Genes Recesivos , Ligamiento Genético , Marcadores Genéticos , Genotipo , Humanos , Litio/uso terapéutico , Escala de Lod , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Fosfolipasa C gamma , Valores de Referencia , Estadísticas no Paramétricas
13.
J Affect Disord ; 50(2-3): 91-6, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9858068

RESUMEN

BACKGROUND: This study explored the nature of the association between bipolar disorder and alcoholism. METHODS: The authors studied 814 first-degree relatives of 121 bipolar patients, divided on the basis of response to lithium prophylaxis. Logistic regression analysis was used to analyze the contribution of demographic, familial and clinical variables to the risk of primary alcoholism in the relatives. RESULTS: The risk of primary alcoholism in relatives was not related to the degree of affective loading in the family or to the proband's lithium response. CONCLUSION: This study does not support a shared genetic liability between bipolar disorder and alcoholism. LIMITATIONS: This study lacked a control group, but the analysis accounted for this. CLINICAL RELEVANCE: These disorders are not alternative forms of the same illness.


Asunto(s)
Alcoholismo/genética , Trastorno Bipolar/genética , Predisposición Genética a la Enfermedad , Adulto , Anciano , Alcoholismo/complicaciones , Trastorno Bipolar/complicaciones , Diagnóstico Dual (Psiquiatría) , Salud de la Familia , Femenino , Humanos , Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Factores de Riesgo , Resultado del Tratamiento
14.
Acta Psychiatr Scand ; 93(6): 447-50, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8831861

RESUMEN

We have studied the gender and family history differences with regard to age of onset of schizophrenia. These differences have often been viewed as an important clue to the aetiology of the illness. Patients from three centres in Europe and Canada were included in the study. A sample of 1089 subjects was categorized according to the subject's sex, family history of schizophrenia, and the centre. The principal statistical method was analysis of variance. Patients with no family history of schizophrenia had a consistently higher average age of onset. This effect was seen in both male and female subjects across all three groups. These results support the relationship between familial risk and early onset, but no interaction of gender and family history was found.


Asunto(s)
Edad de Inicio , Esquizofrenia/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esquizofrenia/genética , Psicología del Esquizofrénico
15.
Sb Lek ; 97(1): 71-95, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8711419

RESUMEN

102 patients were divided into 3 groups: epileptics, psychotics and epileptics with psychotic symptoms. All had long been monitored for a number of clinical and laboratory parameters. Though different in many respects, all share states of sudden dysphoria, cacophoria, panic anxiety, horror, and EEG (stereo-EEG, too) signs of epileptic or other gross anomalies, often correlated to those affective disorders. Attacks of dysphoria, epilepsy, and psychosis come spontaneously and in response to biological (hypoglycemia, sleep deprivation, alcohol, menses) or psychosocial stimulation (agitation, quarrels, fear of redundancy, psychic trauma). These states (attacks, dysphoria, "neurotic" or even psychotic episodes) often provoke one another. -Calling this syndrome epileptosis, we believe its mechanism is due to lesions of the limbic and brainstem modulation systems. At the start of the process there is an epileptic focus in the amygdalo-hippocampal complex (AHC) which in itself can trigger simple or complex partial paroxysm but also-by means of electric stimulation of the AHC-states of dysphoria, anxiety, and psychotic hallucinations. Besides, a form of pathological learning develops in premorbid "hypersensitive" personality which can be put down to associative learning and to Overton's phenomenon of "state-dependent retention of learned responses". This may give rise to mutual stimulation where epileptic focal activity in AHC can provoke dysphoria while an external psychosocial situation can trigger epileptic activity there, too (AHC). Since there need not always be mydriasis (though other vegetative signs such as tachycardia, tachypnoea, nausea, blush and others are frequent) or unconsciousness, and some psychomotor manifestations may be out of the ordinary, and scalp EEG may be normal, such patients are often regarded as "hysterics" or malingerers.


Asunto(s)
Epilepsia/complicaciones , Trastornos Psicóticos/complicaciones , Adulto , Anciano , Diagnóstico Diferencial , Electroencefalografía , Epilepsia/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndrome
16.
Cesk Psychiatr ; 90(6): 328-40, 1994 Dec.
Artículo en Checo | MEDLINE | ID: mdl-7859323

RESUMEN

The authors present a basic review on clozapine (Leponex, Clozaril) which is one of the atypical antipsychotic drugs. It is a derivative of dibenzodiazepine, which contrary to classical neuroleptic drugs, does not exert a marked effect on the extrapyramidal system and its long-term use is not associated with the risk of development of irreversible tardive dyskinesia or dystonia. It is effective also in patients who are resistant to treatment with other neuroleptics and it has a more favourable effect on the negative symptoms of schizophrenia than classical neuroleptics. Its disadvantage is the increased risk of granulocytopenia and agranulocytosis (2%) and therefore its use is justified only in patients where there is evidence that they are resistant to other treatment. The mentioned risk can be controlled effectively by regular checks of the haemogram in patients taking clozapine, along with recording in the central data bank which has a consulting and control function and guaranteeing the method of correct administration of this drug and early therapeutic provisions in case of granulocytopenia. Despite the cost of treatment and checks of the haemogram, clozapine reduces the sum total of expenditure associated with the treatment of chronic schizophrenia by reducing the number of re-admissions to hospital, by shortening the period of hospitalization and by cutting indirect costs, which are influenced by a greater sociability of the patient and a greater probability of successful comprehensive therapeutic procedures.


Asunto(s)
Clozapina , Clozapina/efectos adversos , Clozapina/farmacocinética , Clozapina/uso terapéutico , Humanos
17.
Acta Psychiatr Scand ; 90(4): 304-10, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7832003

RESUMEN

A better understanding of the role of genetic factors in affective disorders is likely to result from investigating more homogeneous populations. To achieve this goal, we have systematically studied patients who are excellent responders to long-term lithium treatment and their relatives. In the families of 71 such probands, we have analyzed the mode of inheritance by comparing the observed morbidity risks with the risks expected under different genetic models. The results demonstrate major-gene effects in the transmission of primary affective disorders; the polygenic model with sex-specific thresholds could be rejected. Discrimination between the autosomal and X-chromosome models was not possible, but the autosomal recessive model predicts more realistic, gender-specific frequencies of affective disorders in the general population. These results suggest that autosomal recessive inheritance deserves serious consideration in molecular genetic investigations.


Asunto(s)
Trastorno Bipolar/genética , Trastorno Depresivo/genética , Litio/uso terapéutico , Adulto , Anciano , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/psicología , Aberraciones Cromosómicas/genética , Trastornos de los Cromosomas , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/psicología , Femenino , Ligamiento Genético/genética , Humanos , Masculino , Persona de Mediana Edad , Familia de Multigenes/genética , Escalas de Valoración Psiquiátrica , Aberraciones Cromosómicas Sexuales/genética , Resultado del Tratamiento , Cromosoma X
18.
J Affect Disord ; 32(2): 85-95, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7829768

RESUMEN

The authors have carried out an investigation of psychiatric morbidity in families of patients who responded and failed to respond to long-term lithium treatment. The study included 121 probands with RDC primary affective disorders and 903 first-degree relatives and spouses. Seventy-one probands were responders and 50 were nonresponders to long-term lithium treatment. Extended to 20 years, the follow-up of patients and their families provided substantial information relevant for the diagnosis and reliable assessment of lithium response. The diagnoses were based on all available information, SADS-L interviews and RDC criteria. The principal statistical methods were survival analysis and Cox regression analysis. The results revealed a significantly higher frequency of bipolar disorder in the relatives of lithium responders (3.8% vs. 0%). Schizophrenia was more common in the families of nonresponders (2.4% vs. 0.3%). There were no significant differences in the rates of other psychiatric disorders. Both family history and the proband's diagnosis contribute independently to predicting response to long-term lithium.


Asunto(s)
Trastorno Bipolar/genética , Trastorno Depresivo/genética , Carbonato de Litio/uso terapéutico , Trastornos Psicóticos/genética , Adulto , Anciano , Trastorno Bipolar/sangre , Trastorno Bipolar/tratamiento farmacológico , Trastorno Depresivo/sangre , Trastorno Depresivo/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Carbonato de Litio/efectos adversos , Carbonato de Litio/farmacocinética , Masculino , Persona de Mediana Edad , Determinación de la Personalidad , Trastornos Psicóticos/sangre , Trastornos Psicóticos/tratamiento farmacológico
19.
Brain Res ; 626(1-2): 322-6, 1993 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-8281444

RESUMEN

In winter, a 5-day exposure of 4 human subjects to a skeleton photoperiod, with 3 h of bright light in the evening and again in the morning, phase advanced the morning serum melatonin offset by 1-3 h as compared with the original winter melatonin rhythm pattern. The phase advance persisted for 3 days even after the bright light withdrawal. The data indicate that the long skeleton photoperiod had a prevailing phase-advancing effect on the melatonin rhythm and its underlying pacemaker. The maintenance of the phase advance might be due to the fixed sleep-wake schedule.


Asunto(s)
Ritmo Circadiano/fisiología , Fotoperiodo , Transducción de Señal/fisiología , Adulto , Femenino , Humanos , Masculino , Melatonina/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA